Enzo Biochem/GeneNews ink colorectal cancer test pact
This article was originally published in The Gray Sheet
Enzo gains rights to market GeneNews' ColonSentry colorectal cancer test in New York and New Jersey under an agreement announced Nov. 18. The firm said it hopes to launch the test in the second half of 2010 after securing CLIA certification and third-party reimbursement. According to GeneNews, ColonSentry is the first blood test for colorectal cancer, and offers a non-invasive method of assessing cancer risk that may improve screening compliance rates and lead to earlier detection
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.